Clinical Trial

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Study acronym: PORTAL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The PORTAL study will test a new combination of drugs (glofitamab, polatuzumab vedotin and obinutuzumab) in patients with large B-cell lymphoma (LBCL) that has come back (relapsed) or not responded to previous treatment. It will determine how safe and effective the combination of these cancer drugs is in treating LBCL before and after CAR-T cell therapy.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-10-03; most recent amendment 2024-12-18.
Status change: Not Yet Recruiting → Recruiting 2024-07-10
Trial Details
NCT Number NCT06071871
Lead Sponsor University College, London
Collaborators: Hoffmann-La Roche
Conditions Large B-cell Lymphoma
Enrollment 99 participants
Start Date 2024-08-16
Primary Completion 2027-07-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-24